Skip to content
2000
image of Toxoplasma gondii Coinfection in HIV-Positive Patients at a Tertiary Care Hospital

Abstract

Introduction

() can cause serious complications in both immunocompetent and immunosuppressed individuals. This study aims to assess the seroprevalence of among HIV-positive individuals and to investigate its association with age, sex, CD4+ T cell count, HIV RNA levels, and hematological parameters.

Methods

This study included 247 HIV-positive individuals followed up at a tertiary care hospital between November 1, 2022, and November 30, 2024. We analyzed serum samples for IgG antibodies using electrochemiluminescent microparticle immunoassay.

Results

The prevalence of IgG seropositivity was found to be 32.8% (n=81; 95% CI: 26.9-39). The median age of seropositive individuals was 52 years (IQR: 42-61), which was significantly higher compared to seronegative individuals (<0.001). The highest IgG seropositivity rate (66.7%) was observed in the 61-80 age group. Hemoglobin levels were significantly lower in IgG seropositive individuals (=0.040). Logistic regression analysis indicated an increased risk of infection with advancing age. The odds ratio for the 41-60 age group was 13.3 (95% CI: 1.6-106, =0.02), while for the 61-80 age group, it was 28 (95% CI: 3.3-240, =0.002).

Discussion

The seroprevalence of in HIV-positive individuals was lower than both global and regional averages. Age was identified as an independent risk factor for seropositivity. Additionally, hematological alterations associated with anemia were observed in seropositive individuals. Further large-scale, multi-center, and regionally representative studies are required to optimize infection management and screening strategies in people living with HIV.

Conclusion

These findings suggest that infection in HIV-positive individuals increases with age and may be associated with anemia, highlighting the need for age-focused screening and management strategies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X392027250704053346
2025-07-14
2025-09-22

  • From This Site

    /content/journals/chr/10.2174/011570162X392027250704053346
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Daher D. Shaghlil A. Sobh E. Hamie M. Hassan M.E. Moumneh M.B. Itani S. El Hajj R. Tawk L. El Sabban M. El Hajj H. Comprehensive overview of Toxoplasma gondii-induced and associated diseases. Pathogens 2021 10 11 1351 10.3390/pathogens10111351 34832507
    [Google Scholar]
  2. Brito R.M.M. de Lima Bessa G. Bastilho A.L. Dantas-Torres F. de Andrade-Neto V.F. Bueno L.L. Fujiwara R.T. Magalhães L.M.D. Genetic diversity of Toxoplasma gondii in South America: occurrence, immunity, and fate of infection. Parasit. Vectors 2023 16 1 461 10.1186/s13071‑023‑06080‑w 38115102
    [Google Scholar]
  3. Ajioka J.W. Morrissette N.S. A century of Toxoplasma research. Int. J. Parasitol. 2009 39 8 859 860 10.1016/j.ijpara.2009.02.006 19248783
    [Google Scholar]
  4. S Al-Malki E. Toxoplasmosis E. Toxoplasmosis: stages of the protozoan life cycle and risk assessment in humans and animals for an enhanced awareness and an improved socio-economic status. Saudi J. Biol. Sci. 2021 28 1 962 969 10.1016/j.sjbs.2020.11.007 33424388
    [Google Scholar]
  5. Khairullah A.R. Kurniawan S.C. Widodo A. Effendi M.H. Hasib A. Silaen O.S.M. Ramandinianto S.C. Moses I.B. Riwu K.H.P. Yanestria S.M. Samodra M.E.E. Afnani D.A. A comprehensive review of toxoplasmosis: Serious threat to human health. Open Public Health J. 2024 17 1 e18749445281387 10.2174/0118749445281387240202094637
    [Google Scholar]
  6. Lee K.H. Jiamsakul A. Kiertiburanakul S. Borse R. Khol V. Yunihastuti E. Azwa I. Somia I.K.A. Chaiwarith R. Pham T.N. Khusuwan S. Do C.D. Kumarasamy N. Gani Y. Ditangco R. Ng O.T. Pujari S. Lee M.P. Avihingsanon A. Chen H.P. Zhang F. Tanuma J. Ross J. Choi J.Y. Risk factors for toxoplasmosis in people living with HIV in the Asia-Pacific region. PLoS One 2024 19 7 e0306245 10.1371/journal.pone.0306245 38950027
    [Google Scholar]
  7. Akins G.K.H. Furtado J.M. Smith J.R. Diseases caused by and behaviors associated with Toxoplasma gondii infection. Pathogens 2024 13 11 968 10.3390/pathogens13110968 39599521
    [Google Scholar]
  8. Sakikawa M. Noda S. Hanaoka M. Nakayama H. Hojo S. Kakinoki S. Nakata M. Yasuda T. Ikenoue T. Kojima T. Anti-Toxoplasma antibody prevalence, primary infection rate, and risk factors in a study of toxoplasmosis in 4,466 pregnant women in Japan. Clin. Vaccine Immunol. 2012 19 3 365 367 10.1128/CVI.05486‑11 22205659
    [Google Scholar]
  9. Asfaram S. Iranpour S. Molaei S. Abdollahzadeh H. Faraji F. Aminizadeh S. Sero-prevalence of Toxoplasma gondii before and during the COVID-19 pandemic in Northwestern Iran. BMC Infect. Dis. 2024 24 1 834 10.1186/s12879‑024‑09724‑z 39152395
    [Google Scholar]
  10. Li Y. Zhou H. Moving towards improved vaccines for Toxoplasma gondii. Expert Opin. Biol. Ther. 2018 18 3 273 280 10.1080/14712598.2018.1413086 29216783
    [Google Scholar]
  11. Li Y. Viscidi R.P. Kannan G. McFarland R. Pletnikov M.V. Severance E.G. Yolken R.H. Xiao J. Chronic Toxoplasma gondii infection induces anti-N-methyl-DAspartate receptor autoantibodies and associated behavioral changes and neuropathology. Infect. Immun. 2018 86 10 e00398-18 10.1128/IAI.00398‑18 30037790
    [Google Scholar]
  12. Robert-Gangneux F. Dardé M.L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin. Microbiol. Rev. 2012 25 2 264 296 10.1128/CMR.05013‑11 22491772
    [Google Scholar]
  13. Cenci-Goga B.T. Rossitto P.V. Sechi P. McCrindle C.M.E. Cullor J.S. Toxoplasma in animals, food, and humans: an old parasite of new concern. Foodborne Pathog. Dis. 2011 8 7 751 762 10.1089/fpd.2010.0795 21486145
    [Google Scholar]
  14. Bakir A. Guney M. Determination of low IgG class antibody avidity percentage by IgM levels specific to Toxoplasma gondii. Clin. Lab. 2022; 68(8). 10.7754/Clin.Lab.2021.211112 35975508
    [Google Scholar]
  15. Pinto-Ferreira F. Caldart E.T. Pasquali A.K.S. Mitsuka-Breganó R. Freire R.L. Navarro I.T. Patterns of transmission and sources of infection in outbreaks of human toxoplasmosis. Emerg. Infect. Dis. 2019 25 12 2177 2182 10.3201/eid2512.181565 31742524
    [Google Scholar]
  16. Rapalino O. Mullins M.E. Intracranial infectious and inflammatory diseases presenting as neurosurgical pathologies. Neurosurgery 2017 81 1 10 28 10.1093/neuros/nyx201 28575459
    [Google Scholar]
  17. Sonneville R. Magalhaes E. Meyfroidt G. Central nervous system infections in immunocompromised patients. Curr. Opin. Crit. Care 2017 23 2 128 133 10.1097/MCC.0000000000000397 28169858
    [Google Scholar]
  18. Wang Z.D. Liu H.H. Ma Z.X. Ma H.Y. Li Z.Y. Yang Z.B. Zhu X.Q. Xu B. Wei F. Liu Q. Toxoplasma gondii infection in immunocompromised patients: A systematic review and meta-analysis. Front. Microbiol. 2017 8 389 10.3389/fmicb.2017.00389 28337191
    [Google Scholar]
  19. Dian S. Ganiem A.R. Ekawardhani S. Cerebral toxoplasmosis in HIV-infected patients: a review. Pathog. Glob. Health 2023 117 1 14 23 10.1080/20477724.2022.2083977 35694771
    [Google Scholar]
  20. Escobar-Guevara E.E. de Quesada-Martínez M.E. Roldán-Dávila Y.B. Alarcón de Noya B. Alfonzo-Díaz M.A. Defects in immune response to Toxoplasma gondii are associated with enhanced HIV-1-related neurocognitive impairment in co-infected patients. PLoS One 2023 18 5 e0285976 10.1371/journal.pone.0285976 37224128
    [Google Scholar]
  21. Ferguson D.J.P. Identification of faecal transmission of Toxoplasma gondii: Small science, large characters. Int. J. Parasitol. 2009 39 8 871 875 10.1016/j.ijpara.2009.01.003 19596630
    [Google Scholar]
  22. Khan A.H. Noordin R. Serological and molecular rapid diagnostic tests for Toxoplasma infection in humans and animals. Eur. J. Clin. Microbiol. Infect. Dis. 2020 39 1 19 30 10.1007/s10096‑019‑03680‑2 31428897
    [Google Scholar]
  23. Li Y. Zeng Y.M. Liu M. Lu Y.Q. Liu X.Y. Zhang Y.L. Jiang Z.S. Yang T.T. Sun Y. Lan K. Chen Y.K. Development of a risk scoring system for prognostication in HIV-related toxoplasma encephalitis. BMC Infect. Dis. 2020 20 1 923 10.1186/s12879‑020‑05651‑x 33276733
    [Google Scholar]
  24. Lakoh S. Jiba D.F. Kanu J.E. Poveda E. Salgado-Barreira A. Sahr F. Sesay M. Deen G.F. Sesay T. Gashau W. Salata R.A. Yendewa G.A. Causes of hospitalization and predictors of HIV-associated mortality at the main referral hospital in Sierra Leone: a prospective study. BMC Public Health 2019 19 1 1320 10.1186/s12889‑019‑7614‑3 31638941
    [Google Scholar]
  25. Menchi-Elanzi M Mayoral AM Morales J Pinargote-Celorio H González-Alcaide G Ramos-Rincón J-M Toxoplasma gondii infection in hospitalized people living with HIV in Spain, 1997 to 2015. Parasitol. Res. 2021 120 2 755 761 10.1007/s00436‑020‑07007‑5
    [Google Scholar]
  26. Wesołowski R. Pawłowska M. Smoguła M. Szewczyk-Golec K. Advances and challenges in diagnostics of toxoplasmosis in hiv-infected patients. Pathogens 2023 12 1 110 10.3390/pathogens12010110 36678458
    [Google Scholar]
  27. Rezanezhad H. Sayadi F. Shadmand E. Nasab S.D.M. Yazdi H.R. Solhjoo K. Kazemi A. Maleki M. Vasmehjani A.A. Seroprevalence of Toxoplasma gondii among HIV patients in Jahrom, Southern Iran. Korean J. Parasitol. 2017 55 1 99 103 10.3347/kjp.2017.55.1.99 28285515
    [Google Scholar]
  28. Kim M. Park S.J. Park H. Trend in serological and molecular diagnostic methods for Toxoplasma gondii infection. Eur. J. Med. Res. 2024 29 1 520 10.1186/s40001‑024‑02055‑4 39468639
    [Google Scholar]
  29. Teimouri A Goudarzi F Goudarzi K Alimi R Sahebi K Foroozand H Toxoplasma gondii infection in immunocompromised patients in Iran (2013-2022): A systematic review and meta-analysis. Iran J. Parasitol. 2022 17 4 443 457 10.18502/ijpa.v17i4.11271
    [Google Scholar]
  30. El-Askary H.M. El-Badry A.A. Shaapan R.M. Ismail M.A.M. Ghieth M.A. Sheemy M.S. Toxoplasma antibodies, Toxoplasma-DNA and antibodies of HCV and HIV in patients with hemodialysis in Beni-Suef, Egypt. Egyp J Veter Sci (Egypt) 2025 56 1239 1246 10.21608/ejvs.2024.284997.2034
    [Google Scholar]
  31. Yenilmez E. Çetinkaya R.A. Difference in Toxoplasma gondii seroprevalence rates due to low and high CD4 counts in patients with HIV/AIDS. Turkiye Parazitol. Derg. 2019 43 1 1 7 10.4274/tpd.galenos.2019.6457 31587535
    [Google Scholar]
  32. Voyiatzaki C. Zare Chormizi A.D. Tsoumani M.E. Efstathiou A. Konstantinidis K. Chaniotis D. Chrysos G. Argyraki A. Papastamopoulos V. Kotsianopoulou M. Seroprevalence of Toxoplasma gondii among HIV positive patients under surveillance in greek infectious disease units: A screening study with comparative evaluation of serological methods. Pathogens 2024 13 5 375 10.3390/pathogens13050375 38787227
    [Google Scholar]
  33. Namme LH Clet B Tchaleu N Mapoure YN Temfack E Doualla MS A cross sectional study. 2004 Available from: https://bmcresnotes.biomedcentral.com/articles/10.1186/1756-0500-6-146
    [Google Scholar]
  34. Piwowarek M. Siennicka K. Mikuła T. Wiercińska-Drapało A. Cerebral toxoplasmosis, cmv and bacterial pneumonia with decreasing CD4+ T-cell count as results of antiretroviral therapy discontinuation—a case report. Pathogens 2021 10 4 497 10.3390/pathogens10040497 33924043
    [Google Scholar]
  35. Safarpour H. Cevik M. Zarean M. Barac A. Hatam-Nahavandi K. Rahimi M.T. Bannazadeh Baghi H. Koshki T.J. Pagheh A.S. Shahrivar F. Ebrahimi M. Ahmadpour E. Global status of Toxoplasma gondii infection and associated risk factors in people living with HIV. AIDS 2020 34 3 469 474 10.1097/QAD.0000000000002424 31714356
    [Google Scholar]
  36. Çağlayık D.Y. Sili U. Tigen T.E. Şengel E.B. Can B. Tunçel T. Doğanç F.B. Meşeci E.B. İlki A. Korten V. Investigation of toxoplasma seropositivity in adult individuals infected with HIV followed at Marmara University Pendik Training and Research Hospital, 2024 Turk Hij Tecr Biyol Derg 2024 81 4 409 418 10.5505/TurkHijyen.2024.40501
    [Google Scholar]
  37. Şenoğlu S. Yeşilbağ Z. Altuntaş A. O. Kumbasar K. H. Kart Y. K. Toxoplasma gondii IgG seroprevalence in patients with HIV/AIDS. Turkish J Parasitol 2018 42 3 175 179 10.5152/tpd.2018.5706 30280690
    [Google Scholar]
  38. Aydin OA Karaosmanoǧlu HK Korkusuz R Nazlican O Toxoplasma gondii IgG seroprevalence in HIV/AIDS patients. Turk. Parazitol. Derg. 2011 35 2 65 67 10.5152/tpd.2011.17
    [Google Scholar]
  39. Zhang X.X. Zhao Q. Shi C.W. Yang W.T. Jiang Y.L. Wei Z.T. Wang C.F. Yang G.L. Seroprevalence and associated risk factors of Toxoplasma gondii infection in the Korean, Manchu, Mongol and Han ethnic groups in eastern and northeastern China. Epidemiol. Infect. 2016 144 9 2018 2024 10.1017/S0950268815003337 26833424
    [Google Scholar]
  40. Rivera E.M. Lavayén S.N. Sánchez P. Martins C.M.A. Gómez E. Rodríguez J.P. Arias M.E. Silva A.P. Angel S.O. Toxoplasma gondii seropositivity associated to peri-urban living places in pregnant women in a rural area of Buenos Aires province, Argentina. Parasite Epidemiol. Control 2019 7 e00121 10.1016/j.parepi.2019.e00121 31872090
    [Google Scholar]
  41. Rostami A. Riahi S.M. Abdollahzadeh Sagha S. Taghipour A. Sepidarkish M. Mohammadnia-Afrouzi M. Ebrahimpour S. Hotez P.J. Gamble R. Gasser R.B. Seroprevalence estimates of latent and acute toxoplasma infections in HIV+ people—call for action in underprivileged communities. Microorganisms 2021 9 10 2034 10.3390/microorganisms9102034 34683355
    [Google Scholar]
  42. Wilking H. Thamm M. Stark K. Aebischer T. Seeber F. Prevalence, incidence estimations and risk factors of Toxoplasma gondii infection in Germany: a representative, cross-sectional, serological study. Sci. Rep. 2016 6 1 22551 10.1038/srep22551 26936108
    [Google Scholar]
  43. Fang E.E. Nyasa R.B. Ndi E.M. Zofou D. Kwenti T.E. Lepezeu E.P. Titanji V.P.K. N Ndip R. Investigating the risk factors for seroprevalence and the correlation between CD4+ T-cell count and humoral antibody responses to Toxoplasma gondii infection amongst HIV patients in the Bamenda Health District, Cameroon. PLoS One 2021 16 12 e0256947 10.1371/journal.pone.0256947 34855762
    [Google Scholar]
  44. Yilmaz A. Vural M.K. Balkan Bozlak C.E. Özhan M.E. Özmen E. Investigation of Toxoplasma gondii serology in different gender and age groups. J. Neurol. 2022 25 1 50 53 10.54614/JANHS.2022.975323
    [Google Scholar]
  45. Daryani A. Sarvi S. Aarabi M. Mizani A. Ahmadpour E. Shokri A. Rahimi M.T. Sharif M. Seroprevalence of Toxoplasma gondii in the Iranian general population: A systematic review and meta-analysis. Acta Trop. 2014 137 185 194 10.1016/j.actatropica.2014.05.015 24887263
    [Google Scholar]
  46. Mohammed A. Ahmed M. Ibrahim N. The global seroprevalence of Toxoplasma gondii infection in workers occupationally exposed to animals (1972–2023): a systematic review and meta-analysis. Vet. Q. 2024 44 1 1 18 10.1080/01652176.2024.2396577 39205625
    [Google Scholar]
  47. Yohanes T. Debalke S. Zemene E. Latent Toxoplasma gondii infection and associated risk factors among HIV-infected individuals at Arba Minch Hospital, south Ethiopia. Aids Res. Treat. 2014 2014 1 6 10.1155/2014/652941 25431660
    [Google Scholar]
  48. Antinori A. Larussa D. Cingolani A. Lorenzini P. Bossolasco S. Finazzi M.G. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis 2004 39 11 1681 1691 10.1086/424877
    [Google Scholar]
  49. Bhandari S. Kc S. Devkota L. Khadka S. Rai G. Bastola A. Rai S.K. Seroprevalence toxoplasma infection among HIV/AIDS patients in Kathmandu, Nepal. Nepal Med. Coll. J. 2021 23 1 72 75 10.3126/nmcj.v23i1.36236
    [Google Scholar]
  50. Eyong E.E.J. Elinor T.S. Moses S. Seroprevalence and risk factors of Toxoplasmosis in HIV positive and negative patients attending the Bamenda Regional Hospital, North West Region, Cameroon. Afr. J. Clin. Exp. Microbiol. 2024 25 4 401 412 10.4314/ajcem.v25i4.4
    [Google Scholar]
  51. Wang Z. Zhang D.X. Zhao Q. Infection-stimulated anemia results primarily from interferon gamma-dependent, signal transducer and activator of transcription 1-independent red cell loss. Chin. Med. J. (Engl.) 2015 128 7 948 955 10.4103/0366‑6999.154303 25836617
    [Google Scholar]
/content/journals/chr/10.2174/011570162X392027250704053346
Loading
Toxoplasma gondii Coinfection in HIV-Positive Patients at a Tertiary Care Hospital
Bentham Science Publishers ; https://doi.org/10.2174/011570162X392027250704053346
/content/journals/chr/10.2174/011570162X392027250704053346
/content/journals/chr/10.2174/011570162X392027250704053346
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Toxoplasma gondii ; seroprevalence ; CD4+ T cell count ; HIV ; risk factors ; IgG

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test